On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

Visit a quote page and your recently viewed tickers will be displayed here.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

3382.T Seven & i Holdings Co., Ltd.